Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study
ESMO 2021: KEYNOTE-716 Study
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
